Advances in Gene Editing Technologies for Cancer Therapy

Zhihan Zheng

doi:10.54254/2753-8818/2025.20327

Research Article

Open access

Published on 15 January 2025

Download pdf

Zheng,Z. (2025). Advances in Gene Editing Technologies for Cancer Therapy. Theoretical and Natural Science,89,52-56.

Export citation

Advances in Gene Editing Technologies for Cancer Therapy

Zhihan Zheng *^,1,

¹ The University of Nottingham-Ningbo

* Author to whom correspondence should be addressed.

https://doi.org/10.54254/2753-8818/2025.20327

Abstract

Using gene editing techniques, cancer treatments are being transformed into new ones that precisely alter genetic patterns. The usefulness, difficulties, and future potential of HDR, Base Editing, and Prime Editing are assessed in this review. While HDR provides accurate gene repair, its specificity and efficiency are not as strong. While base editing shows promise in correcting genetic flaws, it must be used with caution to reduce unintended consequences. A new technique called Prime Editing makes more secure and accurate editing possible without rupturing DNA. Despite their huge potential, advancement in areas like security, ethics, and efficacy of distribution is crucial. The article examines these techniques' potential for treating cancer by compiling research on them.

Keywords

Homology Directed Repair (HDR), Base Editing, Prime Editing, Gene Editing, and Cancer Therapy

View pdf

References

[1]. He K, Xue Q, Zhou W, et al. 2024. 'Extended pegRNAs enhance the editing capability of Prime editing'. Trends in Biotechnology.

[2]. Mok G Y, Hong S, Seo I D, et al. 2024. 'Herbicide-resistant plants produced by precision adenine base editing in plastid DNA'. Nature Plants. (Prepublish): 1-7.

[3]. Johnson A G, Gould I S, Rivera S J F. 2024. 'Deconstructing cancer with precision genome editing'. Biochemical Society Transactions.

[4]. Tao R, Han X, Bai X, et al. 2024. 'Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology'. Frontiers in Immunology, 15, 1354825-1354825.

[5]. Xiong X, Bei J. 2023. 'Gene editing technology in cancer therapy'. Chinese Journal of Cell Biology, 45(12), 1746-1756.

[6]. Ding Y D, Chen C. 2022. 'Research progress of CRISPR-Cas9 gene editing technology in tumor therapy'. Laser Biology Report, 31(06), 488-497.

[7]. Chunling H, R L, E M R, et al. 2022. 'Classification of BRCA2 variants of uncertain significance (VUS) using an ACMG/AMP model incorporating a homology directed repair (HDR) functional assay'. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 28(17).

[8]. Li C G, Mei H, Hu Y. 2019. 'Research progress of gene editing technology in CAR-T therapy'. Chinese Journal of Cancer Biotherapy, 26(03), 338-345.

[9]. Ji H Y, Zhu H Z. 2015. 'Research progress of gene editing technology in gene therapy'. Life Sciences, 27(01), 71-82. DOI: 10.13376/j.cbls/2015012.

Cite this article

Zheng,Z. (2025). Advances in Gene Editing Technologies for Cancer Therapy. Theoretical and Natural Science,89,52-56.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

Disclaimer/Publisher's Note

The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

About volume

Volume title: Proceedings of the 3rd International Conference on Modern Medicine and Global Health

Conference website: https://2025.icmmgh.org/

ISBN：978-1-83558-929-8(Print) / 978-1-83558-930-4(Online)

Conference date: 10 January 2025

Editor：Sheiladevi Sukumaran

Series: Theoretical and Natural Science

Volume number: Vol.89

ISSN：2753-8818(Print) / 2753-8826(Online)

© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open access policy for details).